In this video interview, Heather Horville, solutions consultant at Greenphire, explains how upfront reimbursement, travel stipends, and flexible support services can empower more patients—especially ...

In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...